Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Moscow Clinical Scientific Center
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
untreated early HR+ HER2- BC:
1. planned neoadjuvant chemotherapy: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
